NO20083249L - Imidazolderivater for behandling av gastrointestinale forstyrrelser - Google Patents

Imidazolderivater for behandling av gastrointestinale forstyrrelser

Info

Publication number
NO20083249L
NO20083249L NO20083249A NO20083249A NO20083249L NO 20083249 L NO20083249 L NO 20083249L NO 20083249 A NO20083249 A NO 20083249A NO 20083249 A NO20083249 A NO 20083249A NO 20083249 L NO20083249 L NO 20083249L
Authority
NO
Norway
Prior art keywords
treatment
gastrointestinal disorders
imidazole derivatives
compounds
gabab
Prior art date
Application number
NO20083249A
Other languages
English (en)
Inventor
Udo Bauer
Wayne Brailsford
Linda Gustafsson
Maria Saxin
Tor Svensson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20083249L publication Critical patent/NO20083249L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår nye imidazolderivater som har en positiv allosterisk GABAB reseptor (GBR) modulerende effekt, fremgangsmåter for fremstilling av nevnte forbindelser og deres anvendelse, eventuelt i kombinasjon med en GABAB agonist, for inhibering av forbigående lavere spiserør lukkemuskel relaksasjoner, for behandling av gastro spiserør reflukssykdom, så vel som for behandling av funksjonelle gastrointestinale forstyrrelser og irritabel tarmsyndrom (IBS). Forbindelsene er representert ved den generelle formel (I) hvori R1, R2, R3 og Y er som definert i beskrivelsen. For eksempel kan R1 være fenyl, R2 kan være dimetylamino, R3 kan være alkoksy og Y kan være en tioylamino eller metyl eneaminobundet substituent som inneholder en arylgruppe.
NO20083249A 2005-12-23 2008-07-22 Imidazolderivater for behandling av gastrointestinale forstyrrelser NO20083249L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0502906 2005-12-23
PCT/SE2006/001462 WO2007073298A1 (en) 2005-12-23 2006-12-21 Imidazole derivatives for the treatment of gastrointestinal disorders

Publications (1)

Publication Number Publication Date
NO20083249L true NO20083249L (no) 2008-07-23

Family

ID=38188929

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083249A NO20083249L (no) 2005-12-23 2008-07-22 Imidazolderivater for behandling av gastrointestinale forstyrrelser

Country Status (12)

Country Link
US (1) US7745474B2 (no)
EP (1) EP1966154A4 (no)
JP (1) JP2009521428A (no)
KR (1) KR20080091452A (no)
CN (1) CN101341130A (no)
AU (1) AU2006327315A1 (no)
BR (1) BRPI0620372A2 (no)
CA (1) CA2632016A1 (no)
IL (1) IL191750A0 (no)
NO (1) NO20083249L (no)
WO (1) WO2007073298A1 (no)
ZA (1) ZA200805159B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401653D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
CA2631991A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Heterocyclic gaba-b modulators
CA2632021A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Gaba-b receptor modulators
BRPI0620415A2 (pt) * 2005-12-23 2011-11-08 Astrazeneca Ab composto e sais farmaceuticamente e farmacologicamente aceitáveis do mesmo, e enantiÈmeros do composto e sais do mesmo, composição farmaceutica, e, uso de um composto opcionalmente em combinação com um agonista do receptor de gabab, e, métodos para o tratamento de doença, de um distúrbio, e de sìndrome
KR20080091452A (ko) 2005-12-23 2008-10-13 아스트라제네카 아베 위장 장애의 치료를 위한 이미다졸 유도체
WO2007073299A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Imidazoles as gaba-b receptor modulators
EP2661482B1 (en) 2011-01-04 2016-12-28 The Lubrizol Corporation Continuously variable transmission fluid with extended anti-shudder durability
TW201623257A (zh) 2014-05-09 2016-07-01 奧利安公司 藥理活性之喹唑啉二酮衍生物
GB202414197D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414200D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414199D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel Compounds
GB202414193D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414192D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH449046A (de) 1963-07-09 1967-12-31 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
US3876655A (en) * 1971-08-18 1975-04-08 Beecham Group Ltd Anti-inflammatory acyl imidazoles
US4659720A (en) * 1982-12-20 1987-04-21 Merck & Co., Inc. 5-amino or substituted amino imidazoles useful to treat coccidiosis
GB8425872D0 (en) 1984-10-12 1984-11-21 Ciba Geigy Ag Chemical compounds
GB8624879D0 (en) 1986-10-17 1986-11-19 May & Baker Ltd Compositions of matter
GB8820266D0 (en) 1988-08-26 1988-09-28 Smith Kline French Lab Compounds
GB8911017D0 (en) 1989-05-13 1989-06-28 Ciba Geigy Ag Substituted aminoalkylphosphinic acids
FR2663934B1 (fr) * 1990-06-27 1994-06-03 Adir Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent.
US5214063A (en) * 1990-06-27 1993-05-25 Adir Et Compagnie 4-aminobutyric acid compounds, compositions and methods of use for treating disorders related to a dysfunction of GABAB receptors
DE4213750A1 (de) * 1992-04-25 1993-10-28 Basf Ag Verfahren zur Herstellung von 3-(Hydroxyphenyl)-propionaldehyden und gegebenenfalls der Herstellung von 3-(hydroxyphenyl)-propanolen
US5939419A (en) 1993-02-26 1999-08-17 Schering-Plough Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them
FR2722192A1 (fr) 1994-07-06 1996-01-12 Adir Nouveaux derives de l'acide 4-amino butyrique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU1811397A (en) 1996-02-29 1997-09-16 Kissei Pharmaceutical Co. Ltd. Imidazole derivatives and vascular wall thickening inhibitor
SE9603408D0 (sv) 1996-09-18 1996-09-18 Astra Ab Medical use
SE9904508D0 (sv) 1999-12-09 1999-12-09 Astra Ab New compounds
SE9904507D0 (sv) 1999-12-09 1999-12-09 Astra Ab New compounds
WO2001090141A2 (en) 2000-05-25 2001-11-29 Merck Frosst Canada & Co. Gb1c isoform and nucleotides
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
KR20040033048A (ko) * 2001-09-14 2004-04-17 미츠비시 웰파마 가부시키가이샤 티아졸리딘 유도체 및 이의 약학적 용도
GB0209481D0 (en) 2002-04-24 2002-06-05 Novartis Ag Organic compounds
SE0401653D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
CA2631991A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Heterocyclic gaba-b modulators
KR20080091452A (ko) 2005-12-23 2008-10-13 아스트라제네카 아베 위장 장애의 치료를 위한 이미다졸 유도체
WO2007073299A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Imidazoles as gaba-b receptor modulators
BRPI0620415A2 (pt) * 2005-12-23 2011-11-08 Astrazeneca Ab composto e sais farmaceuticamente e farmacologicamente aceitáveis do mesmo, e enantiÈmeros do composto e sais do mesmo, composição farmaceutica, e, uso de um composto opcionalmente em combinação com um agonista do receptor de gabab, e, métodos para o tratamento de doença, de um distúrbio, e de sìndrome
CA2632021A1 (en) 2005-12-23 2007-06-28 Astrazeneca Ab Gaba-b receptor modulators
CA2682301A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab Xanthine compounds having a positive allosteric gabab receptor modulator effect
US20080262064A1 (en) * 2007-04-18 2008-10-23 Astrazeneca Ab Novel Compounds For The Treatment Of GI Disorders 682

Also Published As

Publication number Publication date
EP1966154A1 (en) 2008-09-10
BRPI0620372A2 (pt) 2011-11-08
KR20080091452A (ko) 2008-10-13
US7745474B2 (en) 2010-06-29
AU2006327315A1 (en) 2007-06-28
CA2632016A1 (en) 2007-06-28
EP1966154A4 (en) 2011-01-26
US20090005428A1 (en) 2009-01-01
IL191750A0 (en) 2008-12-29
JP2009521428A (ja) 2009-06-04
WO2007073298A1 (en) 2007-06-28
ZA200805159B (en) 2009-03-25
CN101341130A (zh) 2009-01-07

Similar Documents

Publication Publication Date Title
NO20083249L (no) Imidazolderivater for behandling av gastrointestinale forstyrrelser
NO20083248L (no) Imidazoler som GABA-B reseptormodulatorer
NO20083247L (no) GABA-B reseptormodulatorer
NO20083243L (no) Pyrazoler for behandling av GERD og IBS
NO20083244L (no) Heterosykliske GABA-B modulatorer
EA201101334A1 (ru) Новые соединения бензотиадиазепина, способ их приготовления и фармацевтические композиции, содержащие их
SE0401653D0 (sv) New compounds
MX2009010893A (es) Compuestos de xantina que tienen un efecto modulador del receptor gabab alosterico positivo.
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
NO20085385L (no) Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
EA201270646A1 (ru) Ингибиторы глюкозилцерамидсинтазы
NO20083057L (no) Sulfonyl substituerte 1H-indoler som ligander til 5-hydroksytryptamin reseptorer
SMT201300085B (it) Composti di pirrolo
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20082934L (no) Antivirale nukleotider
NO20085269L (no) 2-tioksantinderivater som fungerer som MPO-inhibitorer
EA200971044A1 (ru) Арил- и гетероарилзамещенные тетрагидробензо-1,4-диазепины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
NO20063621L (no) Derivater av N-`(1,5-difenyl-1H-pyrazol-3-yl) sulfonamid med CB1 receptoraffinitet
EA201170722A1 (ru) Лактамы в качестве ингибиторов бета-секретазы
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
WO2010003084A3 (en) Phosphodiesterase 4 inhibitors
EA201071269A1 (ru) 3,4-замещенные пиперидиновые производные в качестве ингибиторов ренина
EA201490754A1 (ru) Производные карбамата/мочевины, содержащие пиперидиновые и пиперазиновые кольца, в качестве ингибиторов н3 рецептора

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application